4577 — Daito Pharmaceutical Co Balance Sheet
0.000.00%
- ¥31bn
- ¥39bn
- ¥47bn
- 66
- 74
- 44
- 69
Annual balance sheet for Daito Pharmaceutical Co, fiscal year end - May 31st, JPY millions except per share, conversion factor applied.
2020 May 31st | 2021 May 31st | 2022 May 31st | 2023 May 31st | 2024 May 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Yuho | Yuho | Yuho | Yuho | Yuho |
Standards: | JAS | JAS | JAS | JAS | JAS |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Cash and Short Term Investments | 3,084 | 3,373 | 4,381 | 3,607 | 2,727 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 15,521 | 12,791 | 16,146 | 17,654 | 16,733 |
Total Inventory | |||||
Total Other Current Assets | |||||
Total Current Assets | 30,855 | 32,430 | 37,909 | 40,663 | 41,460 |
Net Property, Plant And Equipment | 19,400 | 21,372 | 23,116 | 25,837 | 31,972 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 54,250 | 57,739 | 64,939 | 70,552 | 77,708 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 15,054 | 12,859 | 14,069 | 15,428 | 18,505 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 17,741 | 16,120 | 17,632 | 19,880 | 25,639 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 36,509 | 41,619 | 47,307 | 50,672 | 52,069 |
Total Liabilities & Shareholders' Equity | 54,250 | 57,739 | 64,939 | 70,552 | 77,708 |
Total Common Shares Outstanding |